Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma
Authors: Michael A. Carducci
Journal: Journal of Clinical Oncology (2023)

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. April 05, 2023 Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. April 05, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.00153 Journal of Clinical Oncology - published online before print April 5, 2023 PMID: 37018918 Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma Michael A. Carducci, MD1,2xMichael A. CarducciSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD https://doi.org/10.1200/JCO.23.00153 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2009, Motzer et al1 demonstrated an overall survival advantage for sunitinib over interferon-α in metastatic clear cell renal carcinoma; in 2010, Sternberg et al2 demonstrated an 8-month improvement in progression-free survival over placebo in the same patient population as sunitinib. These two reports laid the foundation for vascular endothelial growth factor tyrosine kinase inhibition therapy in renal cancer and forming the building blocks for immune checkpoint combination therapies now used in clinical practice further extending the lives of patients with advanced renal cell carcinoma.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell CarcinomaThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Michael A. CarducciThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Pfizer, Acrivon Therapeutics, AstraZeneca, SanofiResearch Funding: Pfizer (Inst), Arcus Biosciences (Inst), Merck (Inst), Celgene/Bristol Myers Squibb (Inst)No other potential conflicts of interest were reported. Companion Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma